# Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer

> **NCT04940325** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 100 (actual)

## Conditions studied

- Metastatic Lung Cancer
- Advanced Non Small Cell Lung Cancer
- Unresectable Non-small Lung Cancer

## Interventions

- **DRUG:** DS-1062a

## Key facts

- **NCT ID:** NCT04940325
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-12
- **Primary completion:** 2028-04
- **Final completion:** 2028-09
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2025-11-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04940325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04940325, "Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT04940325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*